KRAS and non-small cell lung carcinoma: As we utilized NSCLC cell lines with K-Ras mutation, for which molecular target therapy is not available, and a C. elegans multivulva model with EGFR T790M-L858R representing TKI-resistant tumors, our data suggest that IHT and its combination with NR4A1 inhibition are potential strategies to treat NSCLCs.